Decay accelerating factor (DAF) is a glycoprotein present on the surfaces of many types ofcells in contact with plasma, including erythrocytes, leukocytes, and platelets (reviewed in reference 1). A small amount ofDAF is also present in serum. Numerous investigators have demonstrated that DAF inhibits the action of C3 convertases on cell surfaces, and its absence has been shown to be at least partially responsible for the abnormal sensitivity to lysis by complement exhibited by erythrocytes of patients with the acquired stem cell disorder paroxysmal nocturnal hemoglobinuria (PNH) (2). Hereditary absence of DAF has not been previously described .
1994
TELEN ET AL . BRIEF DEFINITIVE REPORT was used to raise a rabbit polyclonal antiserum to DAF (5) ; the resulting antiserum was nonreactive with PNH type III cells, indicating that it did not bind to non-DAF erythrocyte surface proteins .
Antibody reactivity with random donor as well as PNH and phenotypically rare erythrocytes was measured by RIA as previously described (7), except that nadiolabeled Staphylococcal protein A (SPA) was used to detect binding of rabbit antiserum, and F(ab')z sheep antibody to human Ig (heavy and light chains, Amersham Corp., Arlington Heights, IL) was used when human blood group antisera were tested . Competitive inhibition assays were performed as previously described (8) , except that purified proteins were solubilized in 0.1% NP-40 at -700 ug/ml and further diluted in PBS supplemented with 10% BSA . Tc and Cr' antisera were incubated with purified proteins for 1 h at ambient temperature before addition of erythrocytes. All Cromer-related human antisera were reacted with erythrocytes at 37°C .
Erythrocytes from PNH patients were obtained and separated into populations of type I (normal) and type III (markedly sensitive to complement) cells as previously described, using cobra-venom lysis of type III cells to obtain type I cells (9) and anti -acetylcholinesterase affinity chromatography to isolate type III cells (10) . None of the patients studied had appreciable numbers of type II cells (with intermediate sensitivity to complement).
Immunoblotting of erythrocyte proteins was performed as previously described (11), except that binding of human blood group antibodies was detected using "'I-labeled F(ab')z sheep antibody to human Ig (-100,000 cpm/100 ul) and PBS, 0.2% Tween 20 buffer, pH 7 .4 . Reactivity of rabbit antibodies was detected using radiolabeled SPA.
Results
Reactivity of Cromer-related Antibodies with Purified DAF in Solution . Purified DAF was tested for its ability to inhibit binding of antisera against the high frequency Cromer-related antigens Tc a and Cr a to random donor erythrocytes . Prior incubation of antisera with purified DAF was able markedly to inhibit subsequent binding of both Tca and Cra antibodies to erythrocytes . This effect demonstrated a clear dose-response relationship (Fig . 1) Competitive inhibition of Cromer-related antisera by purified DAF. Subsaturing dilutions of anti T'ca (A) and anti-Cr' (B) were first incubated with purified DAF ( ") or purified In(Lu)-related p80 (/) and then reacted with antigen-positive erythrocytes. Binding of radiolabeled antibody to human Ig was then compared with binding in the absence of inhibitor. The degree of inhibition produced by DAF increased with increasing amounts of inhibitor; a similar relationship was not observed when In(Lu)-related p80 was used as inhibitor. (12) or use of BSA solution with similar detergent concentrations as the DAF solution produced no such effect (Fig. 1) . Purified DAF was demonstrated by this method to react with a total of four Tca and Cra antisera (additional data not shown).
Binding of Cromer-related Antibodies to PNH Erythrocytes . Isolated PNH I and PNH III erythrocytes were tested, along with unseparated cells and cells from normal donors, for their ability to bind antisera to the Cromer-related antigens Tca and Cra. For all patients and antibodies tested, PNH I cells bound antibodies to Cromer-related antigens as well or nearly as well as cells from normal donors, while PNH III cells showed reduced or no binding of antiTca and anti-Cr a (Table I) . Some Cromerrelated antibodies reacted weakly with PNH III cells; these results could have been due to contamination of the PNH III cells by small numbers of PNH I cells or to the presence of small amounts of antibody to other antigens in the antisera used. Unseparated PNH erythrocytes showed binding of antiTca and anti-Cra intermediate between that obtained with purified PNH I and PNH III cells, as would be expected.
PNH I and PNH III erythrocytes were also tested by standard agglutination techniques for reactivity with antisera to Cromer-related antigens . Antisena to Cra, Tca, ITC, Wes t', Dr", and Esa all agglutinated PNH I cells but failed to agglutinate PNH III cells .
Immunoblotting When antisera to Tca were used to stain immunoblots of purified DAF, these antisera showed clear reactivity with DAF protein, while no reactivity was detected using nonreactive human serum (Fig. 2) minimal reactivity (mean of three experiments = 1 .1 x background cpm, range = 0.6-1 .3) compared with Cr(a+) Tc(a + ) cells from six donors, which bound anti-DAF strongly (5.7 x background cpm, range = 3 .5-6.6). Immunoblotting of Inab erythrocyte membrane proteins with anti-DAF also failed to show reactivity of antibody with a specific protein band consistent with the known molecular weight of DAF (Fig. 2) .
Discussion
These studies have demonstrated that antibodies to the Cromer-related human blood group antigens Cra and Tca reacted with purified DAF, a glycoprotein that regulates the activation of the complement component C3 on the surface of hematopoietic cells. Soluble purified DAF was able to competitively inhibit binding ofCromerrelated antibodies to erythrocytes, and antiTca and anti-Cra bound to purified DAF but not to other proteins in immunoblots . Moreover, PNH III erythrocytes, which lack DAF, demonstrated reduced or absent reactivity with human antisera to the Tca and Cra antigens, as well as with antisera to other Cromer-related antigens . In contrast, PNH I erythrocytes from the same donors reacted normally with these antisera. These data all demonstrate not only that expression of these antigens is dependent on expression of DAF but also that these antigens reside on the DAF molecule . However, our data do not provide information regarding the topographic relationship of these two epitopes to each other or to the functional domain of the DAF protein. Preliminary studies have shown that binding of Cromer-related antibodies to DAF protein does not inhibit activity of DAF, as measured by the complement lysis sensitivity test (13) .
Identification of DAF as the molecule that carries these Cromer-related blood group antigens is largely consistent with the biochemical characterization of the protein identified by Spring and colleagues (4) . However, they were unable to demonstrate the presence ofN-linked glycans by endoglycosidase F treatment oferythrocyte membrane proteins under nonreducing conditions, while DAF has been shown to bear -3,000 daltons of such oligosaccharides (14) . Most likely, the N-linked oligosaccharides of the DAF protein are not available to enzymatic digestion unless the intruchain disulfide bonds are disrupted . DAF is known to have multiple intruchain disulfide bonds (15) , consistent with observations by Spring and colleagues that Cromer-related antigens are destroyed by reagents that denature such bonds (4). The known variation in molecular weight of DAF from various cell lineages (15) is also consistent with the data obtained with Cromer-related antibodies (4) .
Polymorphisms in the Cromer-related antigens are rare, with the most common being expression of the Tc" antigen, an antigen that occurs in -5% of blacks (reviewed in reference 16) . Since none of the rare Cromer-related antigen phenotypes have been reported to be associated with hemolytic diseases, such polymorphisms most likely do not affect function of the DAF protein as an inhibitor of C3 convertases . However, direct study oferythrocytes with rare Cromer-related phenotypes is needed to confirm that such polymorphisms are not associated with subclinical disease states . Recently, Stafford and colleagues (17) have presented data describing restriction fragment length polymorphisms ofthe gene encoding DAR Also, Sugita et al. (6) described amino acid sequence polymorphisms in the first and fourth amino acids of DAR However, these polymorphisms are most likely not directly related to Tc and Cr blood group antigen polymorphisms, since the latter are of quite low frequency.
Cells of the very rare Inab phenotype bound little or no rabbit polyclonal antibody to DAR This extremely rare null phenotype is therefore likely to represent an inherited inability to express normal DAR Lack of expression of DAF by Inab cells could be due to defective DAF genes or to a processing or insertion defect similar to that proposed for PNH . Although persons with the Inab phenotype have not been described to have hemolytic disease, cells with an isolated DAF defect would be expected to behave like PNH II cells and thus suffer little hemolysis in vivo (1) . However, two of the four persons described to have had this phenotype have also had severe protein-losing enteropathies, suggesting that lack of DAF or lack of another protein genetically linked to expression of DAF and Cromer-related antigens may play a critical role in human gastrointestinal pathophysiology.
